Additional Phase 2 Data of AL-S Pharma's Lead Program AP-101 Further Demonstrate Clinically Meaningful Disease Modification and Prolonged Survival in ALS

Results supported by key neuroaxonal injury biomarkers pNfH and NfL after six months of treatment AP-101 is an investigational human-derived antibody therapeutic that selectively targets the misfolded ...
Nasdaq

MediciNova Announces Poster Presentation of COMBAT-ALS Clinical Trial at the 36th International Symposium on ALS/MND

MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, including macrophage migration inhibitory factor (MIF). It is in late-stage ...
Nasdaq

BrainStorm's NurOwn® Data Selected as Breakthrough Science for Presentation at ISCT 2025 Meeting

--BrainStorm Cell Therapeutics Inc., a leading developer of cellular therapies for neurodegenerative diseases, in collaboration with leading ALS research centers, today announced the acceptance of new ...

Film screening and ALS talk headline USI’s March 29 awareness event

USI hosts Illuminate ALS on March 29 with a film screening, Dr. Richard Bedlack’s presentation, and resources for those affected by ALS.
Seeking Alpha

BrainStorm's NurOwn® Data Selected as Breakthrough Science for Presentation at ISCT 2025 Meeting

NEW YORK, April 29, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of cellular therapies for neurodegenerative diseases, in collaboration with leading ALS research ...